{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:45:46Z","timestamp":1791290746992,"version":"4.3.0"},"reference-count":248,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:00:00Z","timestamp":1574467200000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK103616"],"award-info":[{"award-number":["DK103616"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008590","name":"Dr. Ralph and Marian Falk Medical Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pharmthera.2018.06.015","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T03:39:23Z","timestamp":1530329963000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics"],"prefix":"10.1016","volume":"192","author":[{"given":"John D.","family":"Imig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.06.015_bb0005","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1073\/pnas.0703229104","article-title":"Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo","volume":"104","author":"Ai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0010","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.0811022106","article-title":"Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy","volume":"106","author":"Ai","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0015","first-page":"F790","article-title":"20-HETE agonists and antagonists in the renal circulation","volume":"277","author":"Alonso-Galicia","year":"1999","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bmcl.2010.12.042","article-title":"1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia","volume":"21","author":"Anandan","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.0000047278.28407.C2","article-title":"Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels","volume":"107","author":"Archer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0030","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1074\/jbc.M000278200","article-title":"Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation","volume":"275","author":"Argiriadi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1734-1140(10)70311-X","article-title":"Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids","volume":"62","author":"Arnold","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0040","doi-asserted-by":"crossref","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","article-title":"Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids","volume":"285","author":"Arnold","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0045","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1021\/acs.biochem.6b01037","article-title":"Asymmetric binding and metabolism of polyunsaturated fatty acids (PUFAs) by CYP2J2 epoxygenase","volume":"55","author":"Arnold","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1164\/ajrccm.164.4.2101023","article-title":"Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers","volume":"164","author":"Barber\u00e0","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yjmcc.2012.04.008","article-title":"Role of PI3K\u03b1 and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection","volume":"53","author":"Batchu","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2008.09.711","article-title":"Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model","volume":"46","author":"Batchu","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1476-5381.2010.01093.x","article-title":"Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury","volume":"162","author":"Batchu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1139\/y2012-082","article-title":"Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress","volume":"90","author":"Batchu","year":"2012","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0075","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000246672.72188.bd","article-title":"Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation","volume":"48","author":"Bellien","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0080","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/CIRCULATIONAHA.111.070680","article-title":"Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension","volume":"125","author":"Bellien","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FJC.0b013e318273b007","article-title":"Epoxyeicosatrienoic acid pathway in human health and diseases","volume":"61","author":"Bellien","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0090","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/HYPERTENSIONAHA.112.201087","article-title":"Impaired role of epoxyeicosatrienoic acids in the regulation of basal conduit artery diameter during essential hypertension","volume":"60","author":"Bellien","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0095","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1111\/febs.14100","article-title":"Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury","volume":"284","author":"Bettaieb","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acs.jmedchem.5b01239","article-title":"N-Benzylbenzamides: A novel merged scaffold for orally available dual soluble epoxide hydrolase\/peroxisome proliferator-activated receptor \u03b3 modulators","volume":"59","author":"Bl\u00f6cher","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.yjmcc.2009.01.009","article-title":"Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels","volume":"46","author":"Bodiga","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.110.169797","article-title":"14,15-Dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries","volume":"336","author":"Bukhari","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0115","doi-asserted-by":"crossref","first-page":"H1574","DOI":"10.1152\/ajpheart.01122.2011","article-title":"11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET induced relaxations of bovine coronary and rat mesenteric arteries","volume":"302","author":"Bukhari","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/HYPERTENSIONAHA.114.03179","article-title":"Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an \u03b1-linolenic acid-induced inhibition of soluble epoxide hydrolase","volume":"64","author":"Caligiuri","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0125","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00424-010-0804-6","article-title":"Epoxyeicosatrienoic acids and endothelium-dependent responses","volume":"459","author":"Campbell","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/01.RES.78.3.415","article-title":"Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors","volume":"78","author":"Campbell","year":"1996","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FJC.0000000000000523","article-title":"Orally active epoxyeicosatrienoic acid analogs","volume":"70","author":"Campbell","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.prostaglandins.2015.01.002","article-title":"Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway","volume":"116\u2013117","author":"Cao","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.ki.5002394","article-title":"Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension","volume":"72","author":"Capdevila","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0150","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1074\/jbc.M113.508416","article-title":"The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt","volume":"289","author":"Capdevila","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/med.20071","article-title":"Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends","volume":"27","author":"Capra","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0022-3565(25)11191-9","article-title":"Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites","volume":"260","author":"Carroll","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb5000","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HJH.0000000000001708","article-title":"Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severityof ischemic arrhythmias in rats with angiotensin II-dependent hypertension","volume":"36","author":"\u010cervenka","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0165","doi-asserted-by":"crossref","first-page":"857","DOI":"10.33549\/physiolres.932977","article-title":"Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula","volume":"64","author":"\u010cervenka","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cvr\/cvp134","article-title":"Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function","volume":"83","author":"Chaudhary","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0091270010397049","article-title":"Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects","volume":"52","author":"Chen","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0180","doi-asserted-by":"crossref","first-page":"E563","DOI":"10.1152\/ajpendo.00591.2011","article-title":"Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy","volume":"303","author":"Chen","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0185","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1073\/pnas.261710799","article-title":"Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation","volume":"99","author":"Davis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0190","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMra1008153","article-title":"n-3 fatty acids in cardiovascular disease","volume":"364","author":"De Caterina","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0195","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1194\/jlr.M024448","article-title":"EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides","volume":"53","author":"Decker","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1096\/fj.10-171488","article-title":"Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice","volume":"25","author":"Deng","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7150\/thno.4419","article-title":"Therapeutic Angiogenesis for Treating Cardiovascular Diseases","volume":"2","author":"Deveza","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0210","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.fjc.0000189600.74157.6d","article-title":"An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats","volume":"46","author":"Dorrance","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0215","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.amjhyper.2005.04.019","article-title":"The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension","volume":"18","author":"Dreisbach","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0220","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1074\/jbc.RA117.000298","article-title":"Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia","volume":"293","author":"Edin","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0225","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1021\/jm9005302","article-title":"Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase","volume":"52","author":"Eldrup","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0230","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.117.10392","article-title":"Two pools of epoxyeicosatrienoic acids in humans: Alterations in salt-sensitive normotensive subjects","volume":"71","author":"Elijovich","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0235","first-page":"R1307","article-title":"Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes","volume":"301","author":"Elmarakby","year":"2011","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160380","article-title":"Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria","volume":"11","author":"El-Sikhry","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0245","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1021\/jm900634w","article-title":"14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition","volume":"52","author":"Falck","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0250","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.1021\/jm500262m","article-title":"14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates: carboxylate modifications","volume":"57","author":"Falck","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0255","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmcl.2003.08.060","article-title":"11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression","volume":"13","author":"Falck","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0260","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1021\/jm200132q","article-title":"17(R),18(S)-epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues","volume":"54","author":"Falck","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0265","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/HYPERTENSIONAHA.107.103143","article-title":"Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension","volume":"51","author":"Fischer","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0270","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1194\/jlr.M047357","article-title":"Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway","volume":"55","author":"Fischer","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0275","series-title":"Metabolically robust analogs of Cyp-eicosanoids for the treatment of cardiac disease","author":"Fischer","year":"2017"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0280","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/46816","article-title":"Cytochrome P450 2C is an EDHF synthase in coronary arteries","volume":"401","author":"Fisslthaler","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0285","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/hh2101.099268","article-title":"Cytochrome p450 and vascular homeostasis","volume":"89","author":"Fleming","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.prostaglandins.2006.05.003","article-title":"Epoxyeicosatrienoic acids, cell signaling and angiogenesis","volume":"82","author":"Fleming","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0295","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2007.08.002","article-title":"DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation","volume":"28","author":"Fleming","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0300","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/01.HYP.0000032278.75806.68","article-title":"Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats","volume":"40","author":"Fornage","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb9000","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/01.CIR.0000109487.46725.02","article-title":"Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"109","author":"Fornage","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0305","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/6\/2\/026001","article-title":"Profile of eicosanoids in breath condensate in asthma and COPD","volume":"6","author":"Fritscher","year":"2012","journal-title":"J. Breath Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0310","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00125-017-4260-0","article-title":"Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans","volume":"60","author":"Gangadhariah","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0315","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/CIRCRESAHA.116.310525","article-title":"20-HETE signals through G-protein-coupled receptor GPR75 (G(q)) to affect vascular function and trigger hypertension","volume":"120","author":"Garcia","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0320","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/01.RES.0000018162.87285.F8","article-title":"14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries","volume":"90","author":"Gauthier","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0325","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.phrs.2003.09.014","article-title":"14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries","volume":"49","author":"Gauthier","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0330","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/01.HYP.0000091265.94045.C7","article-title":"14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries","volume":"42","author":"Gauthier","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0335","series-title":"A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of GSK2256294 in healthy volunteers, and single and repeat doses of GSK2256294 in adult male moderately obese smokers","author":"GlaxoSmithKline","year":"2013"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0340","doi-asserted-by":"crossref","first-page":"H47","DOI":"10.1152\/ajpheart.01084.2008","article-title":"Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog","volume":"297","author":"Gross","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0345","doi-asserted-by":"crossref","first-page":"H2838","DOI":"10.1152\/ajpheart.00186.2008","article-title":"Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart","volume":"294","author":"Gross","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0350","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.yjmcc.2006.11.020","article-title":"Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts","volume":"42","author":"Gross","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","article-title":"Soluble epoxide hydrolase: gene structure, expression and deletion","volume":"526","author":"Harris","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0365","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2131\/jts.40.451","article-title":"Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice","volume":"40","author":"Hashimoto","year":"2015","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0370","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1161\/CIRCULATIONAHA.112.127340","article-title":"Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia","volume":"126","author":"Herse","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0375","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cvr\/cvr267","article-title":"N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase","volume":"93","author":"Hou","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0380","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature25013","article-title":"Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy","volume":"552","author":"Hu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0385","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1177\/153537020623101112","article-title":"Epoxyeicosatrienoic acid inhibition alters renal hemodynamics during pregnancy","volume":"231","author":"Huang","year":"2006","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.resuscitation.2007.06.031","article-title":"Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation","volume":"76","author":"Hutchens","year":"2008","journal-title":"Resuscitation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0395","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1021\/jm2001376","article-title":"Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase","volume":"54","author":"Hwang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0400","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/CS20150778","article-title":"Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy","volume":"130","author":"Hye Khan","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0405","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prostaglandins.2016.07.003","article-title":"A dual COX-2\/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat","volume":"125","author":"Hye Khan","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0410","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/CS20130479","article-title":"Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition","volume":"127","author":"Hye Khan","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0415","doi-asserted-by":"crossref","first-page":"F965","DOI":"10.1152\/ajprenal.2000.279.6.F965","article-title":"Eicosanoid regulation of the renal vasculature","volume":"279","author":"Imig","year":"2000","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0420","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.00021.2011","article-title":"Epoxides and soluble epoxide hydrolase in cardiovascular physiology","volume":"92","author":"Imig","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0425","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/HYPERTENSIONAHA.114.03585","article-title":"Epoxyeicosatrienoic acids, hypertension, and kidney injury","volume":"65","author":"Imig","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0430","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10739680701456960","article-title":"Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels","volume":"15","author":"Imig","year":"2008","journal-title":"Microcirculation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0435","first-page":"157","article-title":"Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions","volume":"1","author":"Imig","year":"2010","journal-title":"Front. Vasc. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0440","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0445","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.33.1.408","article-title":"Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A","volume":"33","author":"Imig","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0450","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0455","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","article-title":"An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension","volume":"46","author":"Imig","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0460","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/ajh\/hps011","article-title":"Maternal and fetal epoxyeicosatrienoic acids in normotensive and preeclamptic pregnancies","volume":"26","author":"Jiang","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0465","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/HJH.0000000000001029","article-title":"Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats","volume":"34","author":"J\u00edchov\u00e1","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0470","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.bmcl.2006.07.009","article-title":"Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase","volume":"16","author":"Jones","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0475","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/jcbfm.2013.130","article-title":"Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus","volume":"33","author":"Jouihan","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0480","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","article-title":"Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension","volume":"45","author":"Jung","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0485","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1073\/pnas.92.9.3997","article-title":"Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes","volume":"92","author":"Kang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0490","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1016\/S0021-9258(19)38686-7","article-title":"Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase","volume":"268","author":"Karara","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0495","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.yjmcc.2009.02.028","article-title":"Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells","volume":"46","author":"Katragadda","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0500","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/cvr\/cvp281","article-title":"Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition","volume":"85","author":"Keser\u00fc","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0505","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1096\/fj.12-218040","article-title":"Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity","volume":"27","author":"Khan","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0510","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.113.01949","article-title":"An orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt sensitive rat","volume":"62","author":"Khan","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0515","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/CIRCULATIONAHA.105.535294","article-title":"Role of angiogenesis in cardiovascular disease: a critical appraisal","volume":"112","author":"Khurana","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122683","article-title":"Differential effects of sEH inhibitors on the proliferation and migration of vascular smooth muscle cells","volume":"18","author":"Kim","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0525","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1021\/jm0500929","article-title":"Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility","volume":"48","author":"Kim","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0530","doi-asserted-by":"crossref","first-page":"F971","DOI":"10.1152\/ajprenal.00256.2014","article-title":"Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation","volume":"307","author":"Kim","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0535","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1152\/ajprenal.00531.2014","article-title":"Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy","volume":"308","author":"Kim","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0540","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01213011-200501000-00002","article-title":"Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension","volume":"15","author":"King","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176571","article-title":"Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales","volume":"12","author":"Kitamura","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0550","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1165\/rcmb.2013-0063OC","article-title":"Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension","volume":"51","author":"Klinke","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0555","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.2741\/2889","article-title":"Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia","volume":"13","author":"Koerner","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0560","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2011.12.062","article-title":"Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction","volume":"167","author":"Kompa","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0565","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.prostaglandins.2017.07.002","article-title":"Phosphatase activity of soluble epoxide hydrolase","volume":"133","author":"Kramer","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0570","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","article-title":"American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease","volume":"106","author":"Kris-Etherton","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0575","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.pharmtox.45.120403.100045","article-title":"Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation","volume":"45","author":"Kroetz","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0580","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1440-1681.12204","article-title":"Inhibition of soluble epoxide hydrolase is renoprotective in 5\/6 nephrectomized Ren-2 transgenic hypertensive rats","volume":"41","author":"Kujal","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0585","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2009.02.084","article-title":"Omega-3 polyunsaturated fatty acids and cardiovascular diseases","volume":"54","author":"Lavie","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0590","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bcp.12855","article-title":"Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor","volume":"81","author":"Lazaar","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb8000","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/hmg\/ddl085","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study","volume":"15","author":"Lee","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0595","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/HYPERTENSIONAHA.110.161695","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans","volume":"57","author":"Lee","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0600","article-title":"Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.yjmcc.2016.08.001","article-title":"Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(\u2212\/\u2212) mice","volume":"98","author":"Li","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0610","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1016\/j.bmc.2006.06.005","article-title":"The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase","volume":"14","author":"Li","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0615","article-title":"Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0620","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.yjmcc.2009.08.017","article-title":"Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches","volume":"47","author":"Li","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0625","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2015.05.020","article-title":"Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3\u03b2 signaling pathway","volume":"463","author":"Liang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0630","doi-asserted-by":"crossref","first-page":"F1533","DOI":"10.1152\/ajprenal.00656.2012","article-title":"Nitro-oleic acid protects against adriamycin-induced nephropathy in mice","volume":"305","author":"Liu","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0635","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.111.191247","article-title":"Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor \u03baB signaling","volume":"341","author":"Liu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0640","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.bmcl.2010.09.095","article-title":"Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain","volume":"20","author":"Lo","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0645","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrcardio.2015.137","article-title":"New medical therapies for heart failure","volume":"12","author":"von Lueder","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0650","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1073\/pnas.1103482108","article-title":"Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance","volume":"108","author":"Luria","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0655","doi-asserted-by":"crossref","first-page":"E375","DOI":"10.1152\/ajpendo.00131.2009","article-title":"Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase","volume":"297","author":"Luria","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0660","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI117608","article-title":"Experimental and\/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet","volume":"94","author":"Makita","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0665","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00098.2009","article-title":"Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension","volume":"297","author":"Manhiani","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0670","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156802609788340805","article-title":"Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery","volume":"9","author":"Marino","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0675","series-title":"Subarachnoid hemorrhage and soluble epoxide hydrolase inhibition trial (SUSHI)","author":"Martini","year":"2017"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0680","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ja.2015.58","article-title":"Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase","volume":"68","author":"Matsumoto","year":"2015","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0685","doi-asserted-by":"crossref","first-page":"E6034","DOI":"10.1073\/pnas.1610325114","article-title":"Anti-inflammatory \u03c9-3 endocannabinoid epoxides","volume":"114","author":"McDougle","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010045","article-title":"Design, synthesis and cellular characterization of a dual inhibitor of 5-lipoxygenase and soluble epoxide hydrolase","volume":"22","author":"Meirer","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0695","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.yjmcc.2011.11.015","article-title":"Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure","volume":"52","author":"Merabet","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0700","doi-asserted-by":"crossref","first-page":"H679","DOI":"10.1152\/ajpheart.00533.2009","article-title":"Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling","volume":"298","author":"Merkel","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0705","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1096\/fj.02-0640fje","article-title":"Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR)","volume":"17","author":"Michaelis","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0710","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/sj.bjp.0704101","article-title":"HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme","volume":"133","author":"Miyata","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0715","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0720","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1073\/pnas.96.16.8849","article-title":"Potent urea and carbamate inhibitors of soluble epoxide hydrolases","volume":"96","author":"Morisseau","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0725","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.pharmtox.45.120403.095920","article-title":"Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles","volume":"45","author":"Morisseau","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0730","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0735","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1016\/j.bmcl.2006.07.073","article-title":"Peptidyl-urea based inhibitors of soluble epoxide hydrolases","volume":"16","author":"Morisseau","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0740","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ab.2012.11.017","article-title":"Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries","volume":"434","author":"Morisseau","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0745","doi-asserted-by":"crossref","first-page":"H2128","DOI":"10.1152\/ajpheart.00428.2008","article-title":"Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo","volume":"295","author":"Motoki","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0750","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1001\/jama.296.15.1885","article-title":"Fish intake, contaminants, and human health: evaluating the risks and the benefits","volume":"296","author":"Mozaffarian","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0755","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1172\/JCI27546","article-title":"Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel","volume":"116","author":"Nakagawa","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0765","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"122","author":"Neck\u00e1\u0159","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2004.10.001","article-title":"Epoxide hydrolases: their roles and interactions with lipid metabolism","volume":"44","author":"Newman","year":"2005","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0775","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1073\/pnas.0437724100","article-title":"The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity","volume":"100","author":"Newman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0780","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/1074248409358408","article-title":"Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection","volume":"15","author":"Nithipatikom","year":"2010","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0785","doi-asserted-by":"crossref","first-page":"H537","DOI":"10.1152\/ajpheart.00071.2006","article-title":"Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury","volume":"291","author":"Nithipatikom","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0790","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0795","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/jpet.106.103556","article-title":"Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels","volume":"318","author":"Olearczyk","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0800","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/CS20080039","article-title":"Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats","volume":"116","author":"Olearczyk","year":"2009","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0805","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.05.016","article-title":"Epoxyeicosatrienoic acids and cardioprotection: the road to translation","volume":"74","author":"Oni-Orisan","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0810","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1172\/JCI58128","article-title":"Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice","volume":"122","author":"Panigrahy","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0815","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10565-008-9071-0","article-title":"Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase","volume":"25","author":"Parrish","year":"2009","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-385061-4.00002-7","article-title":"Vascular pharmacology of epoxyeicosatrienoic acids","volume":"60","author":"Pfister","year":"2010","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0825","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1074\/jbc.M112.407981","article-title":"Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1\/2 (ERK1\/2)-mediated phosphorylation","volume":"288","author":"Pidkovka","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0830","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/01.HYP.0000208299.62535.58","article-title":"Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling","volume":"47","author":"Pokreisz","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0835","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2008\/626430","article-title":"A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population","volume":"24","author":"Polonikov","year":"2008","journal-title":"Dis. Markers"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0840","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1074\/jbc.M109.081554","article-title":"The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated","volume":"285","author":"Pozzi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0845","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/acs.jmedchem.6b01287","article-title":"Opportunities and challenges for fatty acid mimetics in drug discovery","volume":"60","author":"Proschak","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0850","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1124\/mol.64.2.482","article-title":"Polymorphisms in human soluble epoxide hydrolase","volume":"64","author":"Przybyla-Zawislak","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0855","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/HJH.0b013e32831aedfa","article-title":"Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats","volume":"27","author":"Revermann","year":"2009","journal-title":"J. Hypertens."},{"issue":"5 Suppl","key":"10.1016\/j.pharmthera.2018.06.015_bb0860","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.2223\/JPED.1553","article-title":"Antileukotrienes in the treatment of asthma and allergic rhinitis","volume":"82","author":"Ribeiro","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0865","doi-asserted-by":"crossref","first-page":"H1020","DOI":"10.1152\/ajpheart.00465.2014","article-title":"Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice","volume":"308","author":"Roche","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0870","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.prostaglandins.2015.04.011","article-title":"Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice","volume":"120","author":"Roche","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0875","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0880","doi-asserted-by":"crossref","DOI":"10.1038\/srep27909","article-title":"Structure of neprilysin in complex with the active metabolite of sacubitril","volume":"6","author":"Schiering","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0885","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0890","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.016","article-title":"Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases","volume":"183","author":"Schunck","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0895","series-title":"Novel eicosanoid derivatives","author":"Schunck","year":"2010"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0900","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/01.RES.0000139436.89654.c8","article-title":"Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42\/p44 MAPK pathway","volume":"95","author":"Seubert","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0905","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0910","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.prostaglandins.2006.05.017","article-title":"Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia\/reperfusion injury","volume":"82","author":"Seubert","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0915","doi-asserted-by":"crossref","first-page":"H1605","DOI":"10.1152\/ajpheart.00471.2013","article-title":"Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke","volume":"305","author":"Shaik","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050751","article-title":"Novel omega-3 fatty acid epoxygenase metabolite reduces kidney fibrosis","volume":"17","author":"Sharma","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0925","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.prostaglandins.2009.04.004","article-title":"8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier","volume":"89","author":"Sharma","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0930","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1016\/j.bmcl.2009.08.006","article-title":"A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors","volume":"19","author":"Shen","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0935","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.bmcl.2009.05.036","article-title":"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors","volume":"19","author":"Shen","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0940","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0945","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.atherosclerosis.2015.02.014","article-title":"Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"239","author":"Shen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0950","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jphp.12251","article-title":"Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats","volume":"66","author":"Shrestha","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175292","article-title":"Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery","volume":"12","author":"Shuey","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0960","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd1226","article-title":"Therapeutic angiogenesis in cardiovascular disease","volume":"2","author":"Simons","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0965","doi-asserted-by":"crossref","first-page":"H795","DOI":"10.1152\/ajpheart.00543.2009","article-title":"Soluble epoxide hydrolase inhibition modulates vascular remodeling","volume":"298","author":"Simpkins","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0970","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2353\/ajpath.2009.080544","article-title":"Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection","volume":"174","author":"Simpkins","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0975","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1073\/pnas.1221972110","article-title":"Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis","volume":"110","author":"Sirish","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0980","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003721","article-title":"Molecular mechanisms and new treatment paradigm for atrial fibrillation","volume":"9","author":"Sirish","year":"2016","journal-title":"Circ. Arrhythm Electrophysiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0985","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fphar.2017.00406","article-title":"Epoxyeicosatrienoic acid analog decreases renal fibrosis by reducing epithelial-to-mesenchymal transition","volume":"8","author":"Skibba","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0990","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.109.157545","article-title":"Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice","volume":"331","author":"Sodhi","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb0995","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1000","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000143832.91812.60","article-title":"Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2","volume":"110","author":"Spiecker","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1005","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2174\/092986710790827843","article-title":"Epoxyeicosatrienoic acid analogs and vascular function","volume":"17","author":"Sudhahar","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1010","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1681\/ASN.2009111110","article-title":"High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC","volume":"21","author":"Sun","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2014.00239","article-title":"Inside epoxyeicosatrienoic acids and cardiovascular disease","volume":"5","author":"Tacconelli","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neures.2016.05.002","article-title":"Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice","volume":"111","author":"Taguchi","year":"2016","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000381515","article-title":"Hypoxia and dysregulated angiogenesis in kidney disease","volume":"1","author":"Tanaka","year":"2015","journal-title":"Kidney Dis. (Basel)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneph.2013.35","article-title":"Angiogenesis and hypoxia in the kidney","volume":"9","author":"Tanaka","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1040","doi-asserted-by":"crossref","DOI":"10.1038\/srep42751","article-title":"Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening","volume":"7","author":"Temml","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1045","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bmcl.2017.02.013","article-title":"Soluble epoxide hydrolase inhibitors of indolinone alkaloids and phenolic derivatives from Cimicifuga dahurica (Turcz.) Maxim","volume":"27","author":"Thao","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1050","series-title":"Evaluation of soluble epoxide hydrolase (s-EH) inhibitor in patients with mild to moderate hypertension and impaired glucose tolerance","author":"Therapeutics","year":"2009"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejps.2010.03.018","article-title":"Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs","volume":"40","author":"Tsai","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FJC.0b013e318185fa3c","article-title":"Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model","volume":"52","author":"Ulu","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FJC.0b013e318298e460","article-title":"Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin II dependent hypertension","volume":"62","author":"Ulu","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FJC.0000000000000094","article-title":"An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension","volume":"64","author":"Ulu","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.07.071","article-title":"Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease","volume":"571","author":"V\u00e1clav\u00edkov\u00e1","year":"2015","journal-title":"Gene"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2018.06.015_bb1080","article-title":"8C.05: Epoxyeicosatrienoic acids are increased in placentas of preeclamptic pregnancies","volume":"33","author":"Vedove","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1055\/s-0029-1243604","article-title":"Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history","volume":"118","author":"Wang","year":"2010","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-3565(24)37347-1","article-title":"Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors","volume":"284","author":"Wang","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1095","doi-asserted-by":"crossref","first-page":"F697","DOI":"10.1152\/ajprenal.00321.2015","article-title":"Protection of nitro-fatty acid against kidney diseases","volume":"310","author":"Wang","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/CS20110215","article-title":"Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls","volume":"121","author":"Ward","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2006.02.021","article-title":"Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking","volume":"190","author":"Wei","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1186\/1471-2407-14-841","article-title":"Elevated 14,15-epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer","volume":"14","author":"Wei","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1085\/jgp.200409140","article-title":"Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways","volume":"124","author":"Wei","year":"2004","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.prostaglandins.2011.09.001","article-title":"CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?","volume":"96","author":"Westphal","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1125","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cmdc.201500575","article-title":"Fragment screening of soluble epoxide hydrolase for lead generation-structure-based hit evaluation and chemistry exploration","volume":"11","author":"Xue","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1135","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.chest.2016.10.058","article-title":"Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers","volume":"151","author":"Yang","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/138920008785821684","article-title":"Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1145","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0003-4975(03)00735-5","article-title":"Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time","volume":"76","author":"Yang","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.abb.2009.05.006","article-title":"The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis","volume":"489","author":"Yang","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1155","doi-asserted-by":"crossref","first-page":"F576","DOI":"10.1152\/ajprenal.00288.2016","article-title":"The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats","volume":"311","author":"Yeboah","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cccn.2004.04.028","article-title":"CYP2C9 allele variants in Chinese hypertension patients and healthy controls","volume":"348","author":"Yu","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1165","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1170","doi-asserted-by":"crossref","first-page":"36059","DOI":"10.1074\/jbc.R100030200","article-title":"Epoxygenase pathways of arachidonic acid metabolism","volume":"276","author":"Zeldin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1175","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1073\/pnas.1410432111","article-title":"Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1180","first-page":"24","article-title":"Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases","volume":"70","author":"Zhang","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1185","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/ATVBAHA.109.186064","article-title":"Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia","volume":"29","author":"Zhang","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1190","first-page":"5261","article-title":"Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice","volume":"33","author":"Zhang","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1195","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/mc.21918","article-title":"Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency","volume":"52","author":"Zhang","year":"2013","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1200","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1161\/STROKEAHA.107.508325","article-title":"Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia","volume":"39","author":"Zhang","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1205","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/01.HYP.0000047877.36743.FA","article-title":"Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with salt-sensitive hypertension","volume":"41","author":"Zhao","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1210","first-page":"1244","article-title":"Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage","volume":"15","author":"Zhao","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1215","doi-asserted-by":"crossref","first-page":"F221","DOI":"10.1152\/ajprenal.00170.2004","article-title":"Renal epoxyeicosatrienoic acid synthesis during pregnancy","volume":"288","author":"Zhou","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1220","article-title":"Renal ischemia\/reperfusion injury in soluble epoxide hydrolase-deficient mice","volume":"11","author":"Zhu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097529","article-title":"Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke","volume":"9","author":"Zuloaga","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.06.015_bb1230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/jmg.38.4.234","article-title":"A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia","volume":"38","author":"Zusterzeel","year":"2001","journal-title":"J. Med. Genet."}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:53:42Z","timestamp":1759010022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":248,"alternative-id":["S0163725818301177"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.015","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}